Cholesterol in women at high cardiovascular risk is less successfully treated than in corresponding men: The Skaraborg Hypertension and Diabetes Project

European Journal of Clinical Pharmacology

Volumn 64, Issue 8, 2008, Pages 815-820

  Mehner, Anita ^a   Lindblad, Ulf ^b,c,d   Råstam, Lennart ^c   Boström, Kristina Bengtsson ^b,c  

^a Skara Health Care Centre   (Sweden)

^b R and D Centre   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d Skaraborgs Institutet   (Sweden)

Author keywords

Cerebrovascular disease; Coronary heart disease; Diabetes; Guidelines; Lipid lowering drugs; Primary care

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SEX DIFFERENCE; STROKE; SWEDEN;

AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CORONARY DISEASE; DATA COLLECTION; DIABETES COMPLICATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PREJUDICE; RISK FACTORS; SEX FACTORS; STROKE; SWEDEN;

EID: 45849128695     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0482-x     Document Type: Article

References (27)

1. Wilson P, D'Agostino R, Levy D, Belanger A, Silbershatz H, Kannel W (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-1847
2. Austin M, Hokanson J, Edwards K (1998) Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81:7B-12B
3. Gordon D, Probstfield J, Garrison R, Neaton J, Castelli W, Knoke J et al (1989) High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 79:8-15
4. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 334:1383-1389
5. Medical Products Agency (1995) Treatment of hyperlipidemia. Information från Läkemedelsverket 3:95
6. Medical Products Agency (2003) New guidelines for treatment with lipid lowering drugs. Information från Läkemedelsverket 14:4
7. Hartz I, Eggen A, Grimsgaard S, Skjold F, Njolstad I (2004) Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study: the Tromso Study 2001. Eur J Clin Pharmacol 60:643-649
8. Cooke C, Hammerash WJ (2006) Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: an analysis of patient data from a Maryland-based health maintenance organization. Clin Ther 28:591-599
9. Heart Protection Study Collaborative Group (2002) Heart Protection Study of Cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22
10. Sigurdsson EL, Thorgeirsson G (2003) Primary prevention of cardiovascular disease. Scand J Prim Health Care 21:68-74
11. Pilote L, Ho V, Lavoie F, Coupal L, Zowall H, Grover SA (2005) Cost-effectivenes of lipid lowering treatment according to lipid level. Can J Cardiol 21:681-687
12. Shepherd J, Blauw G, Murphy M, Bollen E, Buckley B, Cobbe S et al (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623-1630
13. Mungal M, Gaw A, Shepard J (2003) Statin therapy in the elderly: does it make good clinical and economic sense? Drugs Aging 20:263-275
14. Third Joint Task Force of European and Other Societies on Cardiovascular Diseases (2003) Prevention in clinical practice. Eur Heart J 24:1601-1610
15. Bog-Hansen E, Lindblad U, Bengtsson K, Ranstam J, Melander A, Råstam L (1998) Risk factor clustering in patients with hypertension and NIDDM: the Skaraborg Hypertension Project. J Int Med 243:223-232
16. Bengtsson K, Orho-Melander M, Lindblad U, Melander O, Bog-Hansen E, Ranstam J et al (1999) Polymorphism in the angiotensin converting enzyme but not in the angiotensinogen gene is associated with hypertension and type 2 diabetes: the Skaraborg Hypertension Project. J Hypertens 17:1569-1575
17. Miller M, Byington R, Hunninghake D, Pitt B, Furberg C (2000) Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Arch Intern Med 160:343-347
18. Petrella J, Merikle E, Jones J (2007) Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis. Clin Ther 29:742-750
19. Sgadari A, Incalzi R, Onder G, Pedone C, Gambassi G (2000) Lipid-lowering therapy in patients with coronary artery disease: sex or age bias? Arch Intern Med 160:2684-2685
20. Gibson D, Bron N, Richens A, Hounslow N, Sedman A, Whitfield L (1996) Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol 36:242-246
21. Nakajima K, for the S-Polis Group (1999) Sex-related differences in response of plasma lipids to simvastatin: the Saitama postmenopausal lipid intervention study. Clin Ther 21:2047-2057
22. Bog-Hansen E, Lindblad U, Ranstam J, Melander A, Råstam L (2002) Antihypertensive drug treatment in a Swedish community: Skaraborg Hypertension and Diabetes Project. Pharmacoepidemiol Drug Saf 11:45-54
23. Wallenius S, Peura S, Klaukka T, Enlund H (1996) Who is using antihypertensive drugs? A prescription analysis from Finland. Scand J Prim Health Care 14:54-61
24. Larsson CA, Gullberg B, Merlo J, Rastam L, Lindblad U (2005) Female advantage in AMI mortality is reversed in patients with type 2 diabetes in the Skaraborg Project. Diabetes Care 28:2246-2248
25. Sigurdsson EL, Jónsson JS, Thorgeirsson G (2002) Medical treatment and secondary prevention of coronary heart disease in general practice in Iceland. Scand J Prim Health Care 20:10-15
26. Marz W, Wollschlager H, Klein G, Neiss A, Wehling M (1999) Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial). Am J Cardiol 84:7-3
27. Malhotra H, Goa K (2001) Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 61:1835-1881